Editorial: minesapride for irritable bowel syndrome with constipation-authors' reply-Reference-Cited by-同舟云学术

Editorial: minesapride for irritable bowel syndrome with constipation-authors' reply

Published:2020-07-30 Issue:4 Volume:52 Page:715-716
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Hamatani Tatsuto¹^ORCID,Fukudo Shin²^ORCID,Nakada Yosuke¹,Inada Hiroshi¹,Kazumori Kiyoyasu¹,Miwa Hiroto³

Affiliation:

1. Sumitomo Dainippon Pharma Co., Ltd; Osaka Japan

2. Department of Behavioral Medicine; Tohoku University Graduate School of Medicine; Sendai Japan

3. Division of Gastroenterology; Department of Internal Medicine; Hyogo College of Medicine; Nishinomiya Japan

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15972/fullpdf

Reference7 articles.

1. Editorial: minesapride for irritable bowel syndrome with constipation;Black;Aliment Pharmacol Ther,2020

2. Randomised clinical trial: minesapride versus placebo for the irritable bowel syndrome with predominant constipation;Hamatani;Aliment Pharmacol Ther,2020

3. Department of Health and Human Services, Food and Drug Administration [docket no. FDA- 2012-D-0146]: guidance for industry on irritable bowel syndrome-clinical evaluation of drugs for treatment: availability;Kux;Fed Reg,2012

4. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1);Chey;Am J Gastroenterol,2020

5. Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome - Revision 1 https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-medicinal-products-treatment-irritable-bowel-syndrome-revision-1_en.pdf